Некоторые формы симптоматических (структурных) эпилепсий у взрослых

1. Карлов В.А. Эпилепсия у детей и взрослых женщин и мужчин. М.: Медицина, 2010.
[Karlov V.A. Epilepsy in children and adult women and men. Moscow: Meditsina, 2010 (in Russian).]
2. Fisher RS, Acevedo C, Arzimanoglou A et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia 2014; 55 (4): 475–82.
3. Helmers SL, Thurman DJ, Durgin TL et al. Descriptive epidemiology of epilepsy in the U.S. population: a different approach. Epilepsia 2015; 56: 942–8. DOI: 10.1111/epi.13001
4. Gupta S, Kwan P, Faught E et al. Understanding the burden of idiopathic generalized epilepsy in the United States, Europe, and Brazil: an analysis from the National Health and Wellness Survey. Epilepsy Behav 2016; 55: 146–56. DOI: 10.1016/j.yebeh.2015.12.18
5. Мильчакова Л.Е. Эпидемиология эпилепсии в отдельных субъектах Российской федерации: эпидемиология, клиника, социальные аспекты, возможности оптимизации фармакотерапии. Автореф. дис. ... д-ра мед. наук. М., 2008.
[Mil'chakova L.E. Epidemiologiia epilepsii v otdel'nykh sub"ektakh Rossiiskoi federatsii: epidemiologiia, klinika, sotsial'nye aspekty, vozmozhnosti optimizatsii farmakoterapii. Avtoref. dis. ... d-ra med. nauk. Moscow, 2008 (in Russian).]
6. Авакян Г.Н. Вопросы современной эпилептологии. Эпилепсия и пароксизмальные состояния. 2015; 7 (4): 16–21.
[Avakian G.N. Voprosy sovremennoi epileptologii. Epilepsiia i paroksizmal'nye sostoianiia. 2015; 7 (4): 16–21 (in Russian).]
7. Мазина Н.К., Мазин П.В., Кислицын Ю.В., Маркова Е.М. Фармакоэкономические аспекты применения руфинамида при синдроме Леннокса–Гасто. Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2016; 9 (1): 15–22.
[Mazina N.K., Mazin P.V., Kislitsyn Iu.V., Markova E.M. Farmakoekonomicheskie aspekty primeneniia rufinamida pri sindrome Lennoksa–Gasto. Farmakoekonomika. Sovremennaia farmakoekonomika i farmakoepidemiologiia. 2016; 9 (1): 15–22 (in Russian).]
8. Giussani G, Franchi C, Messina P et al.; EPIRES Group Prevalence and incidence of epilepsy in a well-defined population of Northern Italy. Epilepsia 2014; 55: 1526–33. DOI: 10.1111/epi.12748
9. Ngugi AK, Kariuki SM, Bottomley C et al. Incidence of epilepsy: a systematic review and meta-analysis. Neurology 2011; 77: 1005–12. DOI: 10.1212/WNL.0b013e31822cfc90
10. Ngugi AK, Bottomley C, Kleinschmidt I et al. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia 2010; 51: 883–90. DOI: 10.1111/j.1528-1167.2009.02481.x
11. Guerreiro CAM. Epilepsy: is there hope? Indian J Med Res 2016; 144: 657–60. DOI: 10.4103/ijmr.IJMR_1051_16
12. Sloviter RS, Bumanglag AV. Defining “epileptogenesis” and identifying “antiepileptogenic targets” in animal models of acquired temporal lobe epilepsy is not as simple as it might seem. Neuropharmacology 2013; 69: 3–15. DOI: 10.1016/j.neuropharm.2012.01.022
13. Pitkanen A, Lukasiuk K. Molecular and cellular basis of epileptogenesis in symptomatic epilepsy. Epilepsy Behav 2009; 14 (Suppl. 1): 16–25. DOI: 10.1016/j.yebeh.2008.09.023
14. Reddy DS. Neuroendocrine aspects of catamenial epilepsy. Horm Behav 2013; 63, 254–66. DOI: 10.1016/j.yhbeh.2012.04.016
15. Bar-Klein G, Lublinsky S, Kamintsky L et al. Imaging blood–brain barrier dysfunction as a biomarker for epileptogenesis. Brain 2017; 140: 1692–705. DOI: 10.1093/brain/awx073
16. Aroniadou-Anderjaska V, Fritsch B, Qashu F, Braga MF. Pathology and pathophysiology of the amygdala in epileptogenesis and epilepsy. Epilepsy Res 2008; 78: 102–16. DOI: 10.1016/j.eplepsyres.2007.11.011
17. Ashrafi MR, Shams S, Nouri M et al. A probable causative factor for an old problem: selenium and glutathione peroxidase appear to play important roles in epilepsy pathogenesis. Epilepsia 2007; 48: 1750–5. DOI: 10.1111/j.1528-1167.2007.01143.x
18. Loscher W, Brandt C. Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research. Pharmacol Rev 2010; 62: 668–700. DOI: 10.1124/pr.110.003046
19. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia 1993; 34: 453–8. DOI: 10.1111/j.1528-1157.1993.tb02586.x
20. Andrzejczak D. Epilepsy and pro-inflammatory cytokines. Immunomodulating properties of antiepileptic drugs. Neurol Neurochir Pol 2011; 45: 275–85.
21. Tagliaferri F, Compagnone C, Korsic M et al. A systematic review of brain injury epidemiology in Europe. Acta Neurochir (Wien) 2006; 148 (3): 255–68. DOI: 10.1007/s00701-005-0651-y
22. Christensen J. The Epidemiology of posttraumatic epilepsy. Semin Neurol 2015; 35 (3): 218–22.
23. Krueger H, Koot J, Hall RE et al. Prevalence of individuals experiencing the effects of stroke in canada: Trends and projections. Stroke 2015; 46: 2226–31. DOI: 10.1161/STROKEAHA.115.009616
24. Tanaka T, Ihara M. Post-stroke epilepsy. Neurochem Int 2017; 107: 219–28. DOI: 10.1016/j.neuint.2017.02.002.
25. Zelano J. Poststroke epilepsy: update and future directions. Ther Adv Neurol Disord 2016; 9: 424–35. DOI: 10.1177/1756285616654423
26. Pitkänen A, Roivainen R, Lukasiuk K. Development of epilepsy after ischaemic stroke. Lancet Neurol 2016; 15: 185–97. DOI: 10.1016/S1474-4422(15)00248-3
27. Chung JM. Seizures in the acute stroke setting. Neurol Res 2014; 36: 403–6. DOI: 10.1179/1743132814Y.0000000352
28. Barolin GS, Sherzer E. Epileptische Anfalle bei Apoplektikern. Wein Nervenh 1962; 20: 35–47.
29. Бурд Г.С., Гехт А.Б., Лебедева А.В. и др. Эпилепсия у больных ишемической болезнью головного мозга. Журн. неврологии и психиатрии. 1998; 2: 4–8.
[Burd G.S., Gekht A.B., Lebedeva A.V. et al. Epilepsiia u bol'nykh ishemicheskoi bolezn'iu golovnogo mozga. Zhurn. nevrologii i psikhiatrii. 1998; 2: 4–8 (in Russian).]
30. Arboix A, Garcia-Eroles L, Massons JB et al. Predictive factors of early seizures after acute cerebrovascular disease. Stroke 1997; 28 (8): 1590–4.
31. Cheung CM, Tsoi TH, Au-Yeung M, Tang AS. Epileptic seizures after stroke in Chinese patients. J Neurol 2003; 250 (7): 839–43.
32. Kilpatrick CJ, Davis SM, Tress BM et al. Epieptic seizures in acute stroke. Arch Neurol 1990; 47 (2): 157–60.
33. Lamy C, Domigo V, Semah F et al. Early and late seizures after cryptogenic ischemic stroke in young adults. Neurology 2003; 60 (3): 365–6.
34. Rumbach L, Sablot D, Berger E et al. Status Epilepticus in stroke: report on a hospital-based stroke cohort. Neurology 2000; 54 (2): 350–4.
35. Beghi E, D’Alessandro R, Beretta S et al. Incidence and predictors of acute symptomatic seizures after stroke. Neurology 2011; 77: 1785–93.
36. Giroud M, Gras P, Fayolle H et al. Early seizures after acute stroke: a study of 1640 cases. Epilepsia 1994; 35: 959–64.
37. Reddy DS, Bhimani A, Kuruba R et al. Prospects of modeling poststroke epileptogenesis. J Neurosci Res 2017; 95: 1000–16. DOI: 10.1002/jnr.23836
38. Myint PK, Staufenberg EF, Sabanathan K. Post-stroke seizure and post-stroke epilepsy. Postgrad Med J 2006; 82: 568–72. DOI: 10.1136/pgmj.2005.041426
39. Lynch MW, Rutecki PA, Sutula TP. The effects of seizures on the brain. Curr Opin Neurol 1996; 9: 97–102. DOI: 10.1097/00019052-199604000-00007
40. Camilo O, Goldstein LB. Seizures and epilepsy after ischemic stroke. Stroke 2004; 35: 1769–75. DOI: 10.1161/01.STR.0000130989.17100.96
41. Ferlazzo E, Gasparini S, Beghi E et al. Epilepsy in cerebrovascular diseases: Review of experimental and clinical data with meta-analysis of risk factors. Epilepsia 2016; 57: 1205–14. DOI: 10.1111/epi.13448
42. Stefanidou M, Das RR, Beiser AS et al. Incidence of seizures following initial ischemic stroke in a community-based cohort: The Framingham Heart Study. Seizure 2017; 47: 105–10. DOI: 10.1016/j.seizure.2017.03.009
43. So EL, Annegers JF, Hauser WA et al. Population-based study of seizure disorders after cerebral infarction. Neurology 1996; 46: 350–5.
44. Arboix A, Comes E, García-Eroles L et al. Prognostic value of very early seizures for in-hospital mortality in atherothrombotic infarction. Eur Neurol 2003; 50: 78–84. DOI: 10.1159/000072503
45. Lancman ME, Golimstok A, Norscini J et al. Risk factors for developing seizures after a stroke. Epilepsia 1993; 34: 141–3. DOI: 10.1111/j.1528-1157.1993.tb02386.x
46. Serafini A, Gigli GL, Gregoraci G et al. Are Early Seizures Predictive of Epilepsy after a Stroke? Results of a Population-Based Study. Neuroepidemiology 2015; 45: 50–8. DOI: 10.1159/000382078
47. Zhao Y, Li X, Zhang K et al. The progress of epilepsy after stroke. Curr Neuropharmacol 2018; 16: 71–8. DOI: 0.2174/1570159X15666170613083253
48. Alberti A, Paciaroni M, Caso V et al. Early seizures in patients with acute stroke: Frequency, predictive factors, and effect on clinical outcome. Vasc Health Risk Management 2008; 4 (3): 715–20.
49. Devuyst G, Karapanayiotides T, Hottinger I et al. Prodromal and early epileptic seizures in acute stroke. Neurology 2003; 61: 249–52.
50. Paolucci S, Silvestri G, Lubich S et al. Poststroke late seizures and their role in rehabilitation of inpatients. Epilepsia 1997; 38 (3): 266–70.
51. Bateman BT, Claassen J, Willey JZ et al. Convulsive status epilepticus after ischemic stroke and intracerebral hemorrhage: frequency, predictors and impact on outcome in a large administrative dataset. Neurocrit Care 2007; 7: 187–93. 
52. Szaflarski JP, Rackley AY, Klendorfer DO et al. Incidence of seizures in the acute phase of stroke: A population-based study. Epilepsia 2008; 49 (6): 974–81.
53. Kraus JA, Berlit P. Cerebral embolism and epileptic seizures – the role of the embolic source. Acta Neurol Scand 1998; 97: 154–8.
54. Lesser RP, Luders H, Dinner DS et al. Epileptic seizures due to thrombotic and embolic cerebrovascular disease in older patients. Epilepsia 1985; 26: 622–30.
55. Bladin CF, Alexandrov AV, Bellavance A et al. Seizures after stroke: a prospective multicenter study. Arch Neurol 2000; 57: 1617–22.
56. Black SE, Norris JW, Hachinski VC. Poststroke seizures. Stroke 1983; 14: 134.
57. Bogousslavsky JL, Van Melle G, Regli F. The Lausanne Stroke Registry: analysis of 1000 consecutive patients with first stroke. Stroke 1988; 19: 1083–92.
58. Kittner SJ, Sharkness CM, Price TR et al. Infarcts with a cardiac source of embolism in the NINDS Stroke Data Bank: historical features. Neurology 1990; 40: 281–4.
59. Bryndziar T, Sedova P, Kramer NM et al. Seizures following ischemic stroke: Frequency of occurrence and impact on outcome in a long-term population-based study. J Stroke Cerebrovasc Dis 2016; 25: 150–6. DOI: 10.1016/j.jstrokecerebrovasdis.2015.09.008
60. Gilad R, Boaz M, Dabby R et al. Are post intracerebral hemorrhage seizures prevented by anti-epileptic treatment? Epilepsy Res 2011; 95: 227–31. DOI: 10.1016/j.eplepsyres.2011.04.002
61. Lahti A-M, Saloheimo P, Huhtakangas J et al. Poststroke epilepsy in long-term survivors of primary intracerebral hemorrhage. Neurology 2017; 88: 2169–75. DOI: 10.1212/WNL.0000000000004009.
62. Qian C, Löppönen P, Tetri S et al. Immediate, early and late seizures after primary intracerebral hemorrhage. Epilepsy Res 2014; 108: 732–9. DOI: 10.1016/j.eplepsyres.2014.02.020
63. Gilad R. Mnagement of seizures following a stroke: what are the options? Drugs Aging 2012; 129: 533–8.
64. Hesdorffer DC, Benn EKT, Cascino GD et al. Is a first acute symptomatic seizure epilepsy? Mortality and risk for recurrent seizure. Epilepsia 2009; 50: 1102–8. DOI: 10.1111/j.1528-1167.2008.01945.x
65. Tomari S, Tanaka T, Ihara M et al. Risk factors for post-stroke seizure recurrence after the first episode. Seizure 2017; 52: 22–6. DOI: 10.1016/j.seizure.2017.09.007
66. Hemphill JC III, Greenberg SM, Anderson CS et al. Guidelines for the management of spontaneous intracerebral hemorrhage: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2015; 46: 2032–60.
67. Huang CW, Saposnik G, Fang J et al. Influence of seizures on stroke outcomes: a large multicenter study. Neurology 2014; 82: 768–76. DOI: 10.1212/WNL.0000000000000166.
68. Alvarez V. Acute seizures in the acute ischemic stroke setting: a step forward in their description. Neurology2014; 82: 740–1. DOI: 10.1212/WNL.0000000000000176
69. Roozenbeek B, Maas AI, Menon DK. Changing patterns in the epidemiology of traumatic brain injury. Nat Rev Neurol 2013; 9 (4): 231–6. DOI: 10.1038/nrneurol.2013.22
70. GBD 2016 Traumatic Brain Injury and Spinal Cord Injury Collaborators. Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990–2016: a systematic analysis for the Global Burden of Disease Study. Lancet Neurol 2019; 18 (1): 56–87. DOI: 10.1016/S1474-4422(18)30415-0
71. CDC. Report to Congress on Traumatic Brain Injury in the United States: Epidemiology and Rehabilitation 2014. https://www.cdc.gov/traumaticbraininjury/pubs/congress_epi_rehab.html
72. WHO. Projections of mortality and burden of disease, 2002–2030. http://www.who.int/healthinfo/global_burden_disease/projections2002/en/
73. Bolkvadze T, Pitkänen A. Development of post-traumatic epilepsy after controlled cortical impact and lateral fluid-percussion-induced brain injury in the mouse. J Neurotrauma 2012; 29 (5): 789–812. DOI: 10.1089/neu.2011.1954
74. Fisher RS, van Emde Boas W, Blume W et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005; 46 (4): 470–2. DOI: 10.1111/j.0013-9580.2005.66104.x
75. Lowenstein DH. Epilepsy after head injury: an overview. Epilepsia 2009; 50 (Suppl. 2): 4–9.
76. Asikainen I, Kaste M, Sarna S. Early and late posttraumatic seizures in traumatic brain injury rehabilitation patients: brain injury factors causing late seizures and influence of seizures on long-term outcome. Epilepsia 1999; 40: 584–9.
77. Haltiner AM, Temkin NR, Dikmen SS. Risk of seizure recurrence after the first late posttraumatic seizure. Arch Phys Med Rehabil 1997; 78: 835–40.
78. Khan AA, Banerjee A. The role of prophylactic anticonvulsants in moderate to severe head injury. Int J Emerg Med 2010; 22; 3 (3): 187–91.
79. Annegers JF, Hauser WA, Coan SP et al. A population‐based study of seizures after traumatic brain injuries. N Engl J Med 1998; 338: 20–4.
80. Vespa PM, Miller C, McArthur D et al. Nonconvulsive electrographic seizures after traumatic brain injury result in a delayed, prolonged increase in intracranial pressure and metabolic crisis. Crit Care Med 2007; 35 (12): 2830–36.
81. Odebode OT, Sanya EO. Outcome of early posttraumatic seizure: an experience in Nigeria. Niger J Clin Pract 2008; 11 (3): 193–8.
82. Fisher RS. An overview of the 2017 ILAE operational classification of seizure types. Epilepsy Behav 2017; 70 (Part A): 271–3. DOI: 10.1016/j.yebeh.2017.03.022
83. Liu ZM, Chen QX, Chen ZB et al. Clinical analysis on risk factors and prognosis of early post-traumatic epilepsy. Arq Neuropsiquiatr 2019; 77 (6): 375–80. DOI: 10.1590/0004-282X20190071
84. Ferguson PL, Smith GM, Wannamaker BB et al. A population-based study of risk of epilepsy after hospitalization for traumatic brain injury. Epilepsia 2010; 51: 891–8.
85. Annegers JF, Coan SP. The risks of epilepsy after traumatic brain injury. Seizure 2000; 9: 453–7.
86. Cancelliere C, Donovan J, Cassidy JD. Is sex an indicator of prognosis after mild traumatic brain injury: A systematic analysis of the findings of the WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury and the International Collaboration on Mild Traumatic Brain Injury Prognosis. Arch Phys Med Rehabil 2016; 97 (Suppl. 2): S5–18.
87. Tao Xu, Xinyuan Yu, Shu Ou et al. Risk factors for posttraumatic epilepsy: A systematic review and meta-analysis. Epilepsy Behav 2017; 67: 1–6. DOI: 10.1016/j.yebeh.2016.10.026
88. D'Ambrosio R, Perucca E. Epilepsy after head injury. Cur Opin Neurology 2004; 17 (6): 731–5.
89. Weiss GH, Caveness WF. Prognostic factors in the persistence of post-traumatic epilepsy. J Neurosurg 1972; 37 (2): 164–9.
90. Salazar AM, Jabbari B, Vance SC et al. Epilepsy after penetrating head injury. I. Clinical correlates: a report of the Vietnam Head Injury Study. Neurology 1985; 35 (10): 1406–14.
91. Chen W, Li MD, Wang GF et al. Risk of post-traumatic epilepsy after severe head injury in patients with at least one seizure. Neuropsychiatr Dis Treat 2017; 13: 2301–6. DOI: 10.2147/NDT.S141486
92. Jackson JH. Localized convulsions from tumour of the brain. Brain 1882; 5: 364–74.
93. Van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 2007; 6: 421–30.
94. Lote K, Stenwig AE, Skullerud K, Hirschberg H. Prevalence and prognostic significance of epilepsy in patients with gliomas. Eur J Cancer 1998; 34: 98–102.
95. Danfors T, Ribom R, Berntsson SG, Smits A. Epileptic seizures and survival during early disease in grade 2 gliomas. Eur J Neurol 2009; 16: 823–31.
96. Chang EF, Potts MB, Keles GE et al. Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg 2008; 108: 227–35.
97. Schaller B, Ruegg SJ. Brain tumor and seizures: pathophysiology and its implications for treatment revisited. Epilepsia 2003; 44: 1223–32.
98. Engel JJr. Seizures and epilepsy. Philadelphia: FA Davis, 1989; p. 221–39.
99. Kerkhof M, Vecht CJ. Seizure characteristics and prognostic factors of gliomas. Epilepsia 2013; 54: 12–7.
100. Pallud J, Audureau E, Blonski M et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014; 137: 449–62.
101. Sanson M, Marie Y, Paris S et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009; 27: 4150–4.
102. Skardelly M, Brendle E, Noell S et al. Predictors of preoperative and early postoperative seizures in patients with intra-axial primary and metastatic brain tumors: a retrospective observational single center study. Ann Neurol 2015; 78: 917–28.
103. Englot DJ, Magill ST, Han SJ et al. Seizures in supratentorial meningioma: a systematic review and meta-analysis. J Neurosurg 2016; 124: 1552–61.
104. Liigant A, Haldre S, Oun A et al. Seizure disorders in patients with brain tumors. Eur Neurol 2001; 45: 46–51.
105. Lynam LM, Lyons MK, Drazkowski JF et al. Frequency of seizures in patients with newly diagnosed brain tumors: a retrospective review. Clin Neurol Neurosurg 2007; 109: 634–8.
106. Michelucci R, Pasini E, Meletti S et al. Epilepsy in primary cerebral tumors: the characteristics of epilepsy at the onset (results from the PERNO study-Project of Emilia Romagna Region on Neuro-Oncology). Epilepsia 2013; 54: 86–91.
107. Wychowski T, Wang H, Buniak L et al. Considerations in prophylaxis for tumor-associated epilepsy: Prevention of status epilepticus and tolerability of newer generation AEDs. Clin Neurol Neurosurg 2013; 115: 2365–9.
108. Pace A, Bove L, Innocenti P et al. Epilepsy and gliomas: incidence and treatment in 119 patients. J Exp Clin Cancer Res 1998; 17: 479–82.
109. Vecht CJ, Wagner GL, Wilms EB. Treating seizures in patients with brain tumors: Drug interactions between antiepileptic and chemotherapeutic agents. Semin Oncol 2003; 30: 49–52.
110. Akeret K, Serra C, Rafi O et al. Anatomical features of primary brain tumors affect seizure risk and semiology. Neuroimage Clin 2019; 22: 101688. DOI: 10.1016/j.nicl.2019.101688
111. Glauser T, Ben-Menachem E, Bourgeois B et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013; 54: 551–63. DOI: 10.1111/epi.12074
112. Young KD, Okada PJ, Sokolove PE et al. A randomized, double-blinded, placebo-controlled trial of phenytoin for the prevention of early posttraumatic seizures in children with moderate to severe blunt head injury. Ann Emerg Med 2004; 43: 435.
113. Torbic H, Forni A.A, Anger KE et al. Use of antiepileptics for seizure prophylaxis after traumatic brain injury. Am J Health Syst Pharm 2013; 70: 759–66.
114. Chang BS, Lowenstein DH, Quality Standards Subcommittee of the American Academy of Neurology . Practice parameter: antiepileptic drug prophylaxis in severe traumatic brain injury. Neurology 2003; 60: 10–6.
115. Krumholz A, Wiebe S, Gronseth GS et al. Evidence‐based guideline: management of an unprovoked first seizure in adults. Neurology 2015; 84: 1705–13.
116. Ma CY, Xue YJ, Li M et al. Sodium valproate for prevention of early posttraumatic seizures. Chin J Traumatol 2010; 13: 293–6.
117. Glantz MJ, Cole BF et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 54: 1886–93.
118. Temkin NR. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilepsia 2001; 42: 515–24.
119. Бадалян О.Л., Бурд С.Г., Авакян Г.Н. и др. Сравнительная оценка эффективности и безопасности производных вальпроевой кислоты: опыт применения. Эпилепсия и пароксизмальные состояния. 2014; 6 (2): 39–44.
[Badalian O.L., Burd S.G., Avakian G.N. et al. Sravnitel'naia otsenka effektivnosti i bezopasnosti proizvodnykh val'proevoi kisloty: opyt primeneniia. Epilepsiia i paroksizmal'nye sostoianiia. 2014; 6 (2): 39–44. (in Russian).]
120. Бадалян О.Л., Савенков А.А. Современная концепция применения инъекционных вальпроатов при эпилептическом статусе. Consilium Medicum. 2019; 21 (2): 97–100. DOI: 10.26442/20751753.2019.2.190316
[Badalyan O.L., Savenkov A.A. Modern conception of usage of injectable valproates  in status epilepticus. Consilium Medicum. 2019; 21 (2): 97–100. DOI: 10.26442/20751753.2019.2.190316 (in Russian).]
121. Li XN, Shu Q, Su JM et al. Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol Cancer Ther 2005; 4: 1912–22.
122. Fu J, Shao CJ, Chen FR et al. Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines. Neuro-oncol 2010; 12: 328–40.
123. Weller M, Gorlia T, Cairncross JG et al. Prolonged survival with valproic acid use in the EORCT/NCIC temozolomide trial for glioblastoma. Neurology 2011; 77: 1156–64.
124. DeLorenzo RJ, Hauser WA, Towne AR et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology 1996; 46: 1029–35.
125. DeLorenzo RJ, Waterhouse EJ, Towne AR et al. Pepsistant nonconvulsive status epilepticus after the contrile of convulsive status epilepticus. Epilepsia 1998; 39: 833–40.
126. DeLorenzo RJ. Clinical syndromes and epidemiology of status epilepticus. In: H.Luders, S.Noachtar (eds.). Epileptic seizures pathophysiology and clinical semiology. Philadelphia: Churchill Livingstone, 2000; p. 697–710.
127. The drug treatement of status epilepticus in Europe: consensus document from a workshop at the first London Colloquium on Status Epilepticus. Epilepsia 2008; 49 (7): 1277–85.
128. Knake S, Hamer HM, Rosenow F. Status epiltpticus: a critical review. Epilepsy Behav 2009; 15: 10–4.
129. Larch J, Trinka E. Intravenous valproate in status epilepticus. A systematic review of the evidence. Epilepsia 2006; 47: 39–46.
130. Olsen KB, Taubоll E, Gjerstad L. Valproate is an effective, well-tolerated drug for treatment of status epilepticus/serial attacks in adults. Acta Neurol Scand Suppl 2007; 187: 51–4.
131. Yasiry Z, Shorvon SD. The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: a meta-analysis of published studies. Seizure 2014; 23: 167–74.
132. www.rlsnet.ru/tn_index_id_1803.htm
133. Карлов В.А., Андреева О.В. Применение инъекционного депакина при лечении эпилептического статуса. Русский медицинский журнал. 2001; 20 (9): 889–93.
[Karlov V.A., Andreeva O.V. Primenenie in"ektsionnogo depakina pri lechenii epilepticheskogo statusa. Russkii meditsinskii zhurnal. 2001; 20 (9): 889–93 (in Russian).]

1. Karlov V.A. Epilepsy in children and adult women and men. Moscow: Meditsina, 2010 (in Russian).
2. Fisher RS, Acevedo C, Arzimanoglou A et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia 2014; 55 (4): 475–82.
3. Helmers SL, Thurman DJ, Durgin TL et al. Descriptive epidemiology of epilepsy in the U.S. population: a different approach. Epilepsia 2015; 56: 942–8. DOI: 10.1111/epi.13001
4. Gupta S, Kwan P, Faught E et al. Understanding the burden of idiopathic generalized epilepsy in the United States, Europe, and Brazil: an analysis from the National Health and Wellness Survey. Epilepsy Behav 2016; 55: 146–56. DOI: 10.1016/j.yebeh.2015.12.18
5. Mil'chakova L.E. Epidemiologiia epilepsii v otdel'nykh sub"ektakh Rossiiskoi federatsii: epidemiologiia, klinika, sotsial'nye aspekty, vozmozhnosti optimizatsii farmakoterapii. Avtoref. dis. ... d-ra med. nauk. Moscow, 2008 (in Russian).
6. Avakian G.N. Voprosy sovremennoi epileptologii. Epilepsiia i paroksizmal'nye sostoianiia. 2015; 7 (4): 16–21 (in Russian).
7. Mazina N.K., Mazin P.V., Kislitsyn Iu.V., Markova E.M. Farmakoekonomicheskie aspekty primeneniia rufinamida pri sindrome Lennoksa–Gasto. Farmakoekonomika. Sovremennaia farmakoekonomika i farmakoepidemiologiia. 2016; 9 (1): 15–22 (in Russian).
8. Giussani G, Franchi C, Messina P et al.; EPIRES Group Prevalence and incidence of epilepsy in a well-defined population of Northern Italy. Epilepsia 2014; 55: 1526–33. DOI: 10.1111/epi.12748
9. Ngugi AK, Kariuki SM, Bottomley C et al. Incidence of epilepsy: a systematic review and meta-analysis. Neurology 2011; 77: 1005–12. DOI: 10.1212/WNL.0b013e31822cfc90
10. Ngugi AK, Bottomley C, Kleinschmidt I et al. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia 2010; 51: 883–90. DOI: 10.1111/j.1528-1167.2009.02481.x
11. Guerreiro CAM. Epilepsy: is there hope? Indian J Med Res 2016; 144: 657–60. DOI: 10.4103/ijmr.IJMR_1051_16
12. Sloviter RS, Bumanglag AV. Defining “epileptogenesis” and identifying “antiepileptogenic targets” in animal models of acquired temporal lobe epilepsy is not as simple as it might seem. Neuropharmacology 2013; 69: 3–15. DOI: 10.1016/j.neuropharm.2012.01.022
13. Pitkanen A, Lukasiuk K. Molecular and cellular basis of epileptogenesis in symptomatic epilepsy. Epilepsy Behav 2009; 14 (Suppl. 1): 16–25. DOI: 10.1016/j.yebeh.2008.09.023
14. Reddy DS. Neuroendocrine aspects of catamenial epilepsy. Horm Behav 2013; 63, 254–66. DOI: 10.1016/j.yhbeh.2012.04.016
15. Bar-Klein G, Lublinsky S, Kamintsky L et al. Imaging blood–brain barrier dysfunction as a biomarker for epileptogenesis. Brain 2017; 140: 1692–705. DOI: 10.1093/brain/awx073
16. Aroniadou-Anderjaska V, Fritsch B, Qashu F, Braga MF. Pathology and pathophysiology of the amygdala in epileptogenesis and epilepsy. Epilepsy Res 2008; 78: 102–16. DOI: 10.1016/j.eplepsyres.2007.11.011
17. Ashrafi MR, Shams S, Nouri M et al. A probable causative factor for an old problem: selenium and glutathione peroxidase appear to play important roles in epilepsy pathogenesis. Epilepsia 2007; 48: 1750–5. DOI: 10.1111/j.1528-1167.2007.01143.x
18. Loscher W, Brandt C. Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research. Pharmacol Rev 2010; 62: 668–700. DOI: 10.1124/pr.110.003046
19. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia 1993; 34: 453–8. DOI: 10.1111/j.1528-1157.1993.tb02586.x
20. Andrzejczak D. Epilepsy and pro-inflammatory cytokines. Immunomodulating properties of antiepileptic drugs. Neurol Neurochir Pol 2011; 45: 275–85.
21. Tagliaferri F, Compagnone C, Korsic M et al. A systematic review of brain injury epidemiology in Europe. Acta Neurochir (Wien) 2006; 148 (3): 255–68. DOI: 10.1007/s00701-005-0651-y
22. Christensen J. The Epidemiology of posttraumatic epilepsy. Semin Neurol 2015; 35 (3): 218–22.
23. Krueger H, Koot J, Hall RE et al. Prevalence of individuals experiencing the effects of stroke in canada: Trends and projections. Stroke 2015; 46: 2226–31. DOI: 10.1161/STROKEAHA.115.009616
24. Tanaka T, Ihara M. Post-stroke epilepsy. Neurochem Int 2017; 107: 219–28. DOI: 10.1016/j.neuint.2017.02.002.
25. Zelano J. Poststroke epilepsy: update and future directions. Ther Adv Neurol Disord 2016; 9: 424–35. DOI: 10.1177/1756285616654423
26. Pitkänen A, Roivainen R, Lukasiuk K. Development of epilepsy after ischaemic stroke. Lancet Neurol 2016; 15: 185–97. DOI: 10.1016/S1474-4422(15)00248-3
27. Chung JM. Seizures in the acute stroke setting. Neurol Res 2014; 36: 403–6. DOI: 10.1179/1743132814Y.0000000352
28. Barolin GS, Sherzer E. Epileptische Anfalle bei Apoplektikern. Wein Nervenh 1962; 20: 35–47.
29. Burd G.S., Gekht A.B., Lebedeva A.V. et al. Epilepsiia u bol'nykh ishemicheskoi bolezn'iu golovnogo mozga. Zhurn. nevrologii i psikhiatrii. 1998; 2: 4–8 (in Russian).
30. Arboix A, Garcia-Eroles L, Massons JB et al. Predictive factors of early seizures after acute cerebrovascular disease. Stroke 1997; 28 (8): 1590–4.
31. Cheung CM, Tsoi TH, Au-Yeung M, Tang AS. Epileptic seizures after stroke in Chinese patients. J Neurol 2003; 250 (7): 839–43.
32. Kilpatrick CJ, Davis SM, Tress BM et al. Epieptic seizures in acute stroke. Arch Neurol 1990; 47 (2): 157–60.
33. Lamy C, Domigo V, Semah F et al. Early and late seizures after cryptogenic ischemic stroke in young adults. Neurology 2003; 60 (3): 365–6.
34. Rumbach L, Sablot D, Berger E et al. Status Epilepticus in stroke: report on a hospital-based stroke cohort. Neurology 2000; 54 (2): 350–4.
35. Beghi E, D’Alessandro R, Beretta S et al. Incidence and predictors of acute symptomatic seizures after stroke. Neurology 2011; 77: 1785–93.
36. Giroud M, Gras P, Fayolle H et al. Early seizures after acute stroke: a study of 1640 cases. Epilepsia 1994; 35: 959–64.
37. Reddy DS, Bhimani A, Kuruba R et al. Prospects of modeling poststroke epileptogenesis. J Neurosci Res 2017; 95: 1000–16. DOI: 10.1002/jnr.23836
38. Myint PK, Staufenberg EF, Sabanathan K. Post-stroke seizure and post-stroke epilepsy. Postgrad Med J 2006; 82: 568–72. DOI: 10.1136/pgmj.2005.041426
39. Lynch MW, Rutecki PA, Sutula TP. The effects of seizures on the brain. Curr Opin Neurol 1996; 9: 97–102. DOI: 10.1097/00019052-199604000-00007
40. Camilo O, Goldstein LB. Seizures and epilepsy after ischemic stroke. Stroke 2004; 35: 1769–75. DOI: 10.1161/01.STR.0000130989.17100.96
41. Ferlazzo E, Gasparini S, Beghi E et al. Epilepsy in cerebrovascular diseases: Review of experimental and clinical data with meta-analysis of risk factors. Epilepsia 2016; 57: 1205–14. DOI: 10.1111/epi.13448
42. Stefanidou M, Das RR, Beiser AS et al. Incidence of seizures following initial ischemic stroke in a community-based cohort: The Framingham Heart Study. Seizure 2017; 47: 105–10. DOI: 10.1016/j.seizure.2017.03.009
43. So EL, Annegers JF, Hauser WA et al. Population-based study of seizure disorders after cerebral infarction. Neurology 1996; 46: 350–5.
44. Arboix A, Comes E, García-Eroles L et al. Prognostic value of very early seizures for in-hospital mortality in atherothrombotic infarction. Eur Neurol 2003; 50: 78–84. DOI: 10.1159/000072503
45. Lancman ME, Golimstok A, Norscini J et al. Risk factors for developing seizures after a stroke. Epilepsia 1993; 34: 141–3. DOI: 10.1111/j.1528-1157.1993.tb02386.x
46. Serafini A, Gigli GL, Gregoraci G et al. Are Early Seizures Predictive of Epilepsy after a Stroke? Results of a Population-Based Study. Neuroepidemiology 2015; 45: 50–8. DOI: 10.1159/000382078
47. Zhao Y, Li X, Zhang K et al. The progress of epilepsy after stroke. Curr Neuropharmacol 2018; 16: 71–8. DOI: 0.2174/1570159X15666170613083253
48. Alberti A, Paciaroni M, Caso V et al. Early seizures in patients with acute stroke: Frequency, predictive factors, and effect on clinical outcome. Vasc Health Risk Management 2008; 4 (3): 715–20.
49. Devuyst G, Karapanayiotides T, Hottinger I et al. Prodromal and early epileptic seizures in acute stroke. Neurology 2003; 61: 249–52.
50. Paolucci S, Silvestri G, Lubich S et al. Poststroke late seizures and their role in rehabilitation of inpatients. Epilepsia 1997; 38 (3): 266–70.
51. Bateman BT, Claassen J, Willey JZ et al. Convulsive status epilepticus after ischemic stroke and intracerebral hemorrhage: frequency, predictors and impact on outcome in a large administrative dataset. Neurocrit Care 2007; 7: 187–93. 
52. Szaflarski JP, Rackley AY, Klendorfer DO et al. Incidence of seizures in the acute phase of stroke: A population-based study. Epilepsia 2008; 49 (6): 974–81.
53. Kraus JA, Berlit P. Cerebral embolism and epileptic seizures – the role of the embolic source. Acta Neurol Scand 1998; 97: 154–8.
54. Lesser RP, Luders H, Dinner DS et al. Epileptic seizures due to thrombotic and embolic cerebrovascular disease in older patients. Epilepsia 1985; 26: 622–30.
55. Bladin CF, Alexandrov AV, Bellavance A et al. Seizures after stroke: a prospective multicenter study. Arch Neurol 2000; 57: 1617–22.
56. Black SE, Norris JW, Hachinski VC. Poststroke seizures. Stroke 1983; 14: 134.
57. Bogousslavsky JL, Van Melle G, Regli F. The Lausanne Stroke Registry: analysis of 1000 consecutive patients with first stroke. Stroke 1988; 19: 1083–92.
58. Kittner SJ, Sharkness CM, Price TR et al. Infarcts with a cardiac source of embolism in the NINDS Stroke Data Bank: historical features. Neurology 1990; 40: 281–4.
59. Bryndziar T, Sedova P, Kramer NM et al. Seizures following ischemic stroke: Frequency of occurrence and impact on outcome in a long-term population-based study. J Stroke Cerebrovasc Dis 2016; 25: 150–6. DOI: 10.1016/j.jstrokecerebrovasdis.2015.09.008
60. Gilad R, Boaz M, Dabby R et al. Are post intracerebral hemorrhage seizures prevented by anti-epileptic treatment? Epilepsy Res 2011; 95: 227–31. DOI: 10.1016/j.eplepsyres.2011.04.002
61. Lahti A-M, Saloheimo P, Huhtakangas J et al. Poststroke epilepsy in long-term survivors of primary intracerebral hemorrhage. Neurology 2017; 88: 2169–75. DOI: 10.1212/WNL.0000000000004009.
62. Qian C, Löppönen P, Tetri S et al. Immediate, early and late seizures after primary intracerebral hemorrhage. Epilepsy Res 2014; 108: 732–9. DOI: 10.1016/j.eplepsyres.2014.02.020
63. Gilad R. Mnagement of seizures following a stroke: what are the options? Drugs Aging 2012; 129: 533–8.
64. Hesdorffer DC, Benn EKT, Cascino GD et al. Is a first acute symptomatic seizure epilepsy? Mortality and risk for recurrent seizure. Epilepsia 2009; 50: 1102–8. DOI: 10.1111/j.1528-1167.2008.01945.x
65. Tomari S, Tanaka T, Ihara M et al. Risk factors for post-stroke seizure recurrence after the first episode. Seizure 2017; 52: 22–6. DOI: 10.1016/j.seizure.2017.09.007
66. Hemphill JC III, Greenberg SM, Anderson CS et al. Guidelines for the management of spontaneous intracerebral hemorrhage: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2015; 46: 2032–60.
67. Huang CW, Saposnik G, Fang J et al. Influence of seizures on stroke outcomes: a large multicenter study. Neurology 2014; 82: 768–76. DOI: 10.1212/WNL.0000000000000166.
68. Alvarez V. Acute seizures in the acute ischemic stroke setting: a step forward in their description. Neurology2014; 82: 740–1. DOI: 10.1212/WNL.0000000000000176
69. Roozenbeek B, Maas AI, Menon DK. Changing patterns in the epidemiology of traumatic brain injury. Nat Rev Neurol 2013; 9 (4): 231–6. DOI: 10.1038/nrneurol.2013.22
70. GBD 2016 Traumatic Brain Injury and Spinal Cord Injury Collaborators. Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990–2016: a systematic analysis for the Global Burden of Disease Study. Lancet Neurol 2019; 18 (1): 56–87. DOI: 10.1016/S1474-4422(18)30415-0
71. CDC. Report to Congress on Traumatic Brain Injury in the United States: Epidemiology and Rehabilitation 2014. https://www.cdc.gov/traumaticbraininjury/pubs/congress_epi_rehab.html
72. WHO. Projections of mortality and burden of disease, 2002–2030. http://www.who.int/healthinfo/global_burden_disease/projections2002/en/
73. Bolkvadze T, Pitkänen A. Development of post-traumatic epilepsy after controlled cortical impact and lateral fluid-percussion-induced brain injury in the mouse. J Neurotrauma 2012; 29 (5): 789–812. DOI: 10.1089/neu.2011.1954
74. Fisher RS, van Emde Boas W, Blume W et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005; 46 (4): 470–2. DOI: 10.1111/j.0013-9580.2005.66104.x
75. Lowenstein DH. Epilepsy after head injury: an overview. Epilepsia 2009; 50 (Suppl. 2): 4–9.
76. Asikainen I, Kaste M, Sarna S. Early and late posttraumatic seizures in traumatic brain injury rehabilitation patients: brain injury factors causing late seizures and influence of seizures on long-term outcome. Epilepsia 1999; 40: 584–9.
77. Haltiner AM, Temkin NR, Dikmen SS. Risk of seizure recurrence after the first late posttraumatic seizure. Arch Phys Med Rehabil 1997; 78: 835–40.
78. Khan AA, Banerjee A. The role of prophylactic anticonvulsants in moderate to severe head injury. Int J Emerg Med 2010; 22; 3 (3): 187–91.
79. Annegers JF, Hauser WA, Coan SP et al. A population‐based study of seizures after traumatic brain injuries. N Engl J Med 1998; 338: 20–4.
80. Vespa PM, Miller C, McArthur D et al. Nonconvulsive electrographic seizures after traumatic brain injury result in a delayed, prolonged increase in intracranial pressure and metabolic crisis. Crit Care Med 2007; 35 (12): 2830–36.
81. Odebode OT, Sanya EO. Outcome of early posttraumatic seizure: an experience in Nigeria. Niger J Clin Pract 2008; 11 (3): 193–8.
82. Fisher RS. An overview of the 2017 ILAE operational classification of seizure types. Epilepsy Behav 2017; 70 (Part A): 271–3. DOI: 10.1016/j.yebeh.2017.03.022
83. Liu ZM, Chen QX, Chen ZB et al. Clinical analysis on risk factors and prognosis of early post-traumatic epilepsy. Arq Neuropsiquiatr 2019; 77 (6): 375–80. DOI: 10.1590/0004-282X20190071
84. Ferguson PL, Smith GM, Wannamaker BB et al. A population-based study of risk of epilepsy after hospitalization for traumatic brain injury. Epilepsia 2010; 51: 891–8.
85. Annegers JF, Coan SP. The risks of epilepsy after traumatic brain injury. Seizure 2000; 9: 453–7.
86. Cancelliere C, Donovan J, Cassidy JD. Is sex an indicator of prognosis after mild traumatic brain injury: A systematic analysis of the findings of the WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury and the International Collaboration on Mild Traumatic Brain Injury Prognosis. Arch Phys Med Rehabil 2016; 97 (Suppl. 2): S5–18.
87. Tao Xu, Xinyuan Yu, Shu Ou et al. Risk factors for posttraumatic epilepsy: A systematic review and meta-analysis. Epilepsy Behav 2017; 67: 1–6. DOI: 10.1016/j.yebeh.2016.10.026
88. D'Ambrosio R, Perucca E. Epilepsy after head injury. Cur Opin Neurology 2004; 17 (6): 731–5.
89. Weiss GH, Caveness WF. Prognostic factors in the persistence of post-traumatic epilepsy. J Neurosurg 1972; 37 (2): 164–9.
90. Salazar AM, Jabbari B, Vance SC et al. Epilepsy after penetrating head injury. I. Clinical correlates: a report of the Vietnam Head Injury Study. Neurology 1985; 35 (10): 1406–14.
91. Chen W, Li MD, Wang GF et al. Risk of post-traumatic epilepsy after severe head injury in patients with at least one seizure. Neuropsychiatr Dis Treat 2017; 13: 2301–6. DOI: 10.2147/NDT.S141486
92. Jackson JH. Localized convulsions from tumour of the brain. Brain 1882; 5: 364–74.
93. Van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 2007; 6: 421–30.
94. Lote K, Stenwig AE, Skullerud K, Hirschberg H. Prevalence and prognostic significance of epilepsy in patients with gliomas. Eur J Cancer 1998; 34: 98–102.
95. Danfors T, Ribom R, Berntsson SG, Smits A. Epileptic seizures and survival during early disease in grade 2 gliomas. Eur J Neurol 2009; 16: 823–31.
96. Chang EF, Potts MB, Keles GE et al. Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg 2008; 108: 227–35.
97. Schaller B, Ruegg SJ. Brain tumor and seizures: pathophysiology and its implications for treatment revisited. Epilepsia 2003; 44: 1223–32.
98. Engel JJr. Seizures and epilepsy. Philadelphia: FA Davis, 1989; p. 221–39.
99. Kerkhof M, Vecht CJ. Seizure characteristics and prognostic factors of gliomas. Epilepsia 2013; 54: 12–7.
100. Pallud J, Audureau E, Blonski M et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014; 137: 449–62.
101. Sanson M, Marie Y, Paris S et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009; 27: 4150–4.
102. Skardelly M, Brendle E, Noell S et al. Predictors of preoperative and early postoperative seizures in patients with intra-axial primary and metastatic brain tumors: a retrospective observational single center study. Ann Neurol 2015; 78: 917–28.
103. Englot DJ, Magill ST, Han SJ et al. Seizures in supratentorial meningioma: a systematic review and meta-analysis. J Neurosurg 2016; 124: 1552–61.
104. Liigant A, Haldre S, Oun A et al. Seizure disorders in patients with brain tumors. Eur Neurol 2001; 45: 46–51.
105. Lynam LM, Lyons MK, Drazkowski JF et al. Frequency of seizures in patients with newly diagnosed brain tumors: a retrospective review. Clin Neurol Neurosurg 2007; 109: 634–8.
106. Michelucci R, Pasini E, Meletti S et al. Epilepsy in primary cerebral tumors: the characteristics of epilepsy at the onset (results from the PERNO study-Project of Emilia Romagna Region on Neuro-Oncology). Epilepsia 2013; 54: 86–91.
107. Wychowski T, Wang H, Buniak L et al. Considerations in prophylaxis for tumor-associated epilepsy: Prevention of status epilepticus and tolerability of newer generation AEDs. Clin Neurol Neurosurg 2013; 115: 2365–9.
108. Pace A, Bove L, Innocenti P et al. Epilepsy and gliomas: incidence and treatment in 119 patients. J Exp Clin Cancer Res 1998; 17: 479–82.
109. Vecht CJ, Wagner GL, Wilms EB. Treating seizures in patients with brain tumors: Drug interactions between antiepileptic and chemotherapeutic agents. Semin Oncol 2003; 30: 49–52.
110. Akeret K, Serra C, Rafi O et al. Anatomical features of primary brain tumors affect seizure risk and semiology. Neuroimage Clin 2019; 22: 101688. DOI: 10.1016/j.nicl.2019.101688
111. Glauser T, Ben-Menachem E, Bourgeois B et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013; 54: 551–63. DOI: 10.1111/epi.12074
112. Young KD, Okada PJ, Sokolove PE et al. A randomized, double-blinded, placebo-controlled trial of phenytoin for the prevention of early posttraumatic seizures in children with moderate to severe blunt head injury. Ann Emerg Med 2004; 43: 435.
113. Torbic H, Forni A.A, Anger KE et al. Use of antiepileptics for seizure prophylaxis after traumatic brain injury. Am J Health Syst Pharm 2013; 70: 759–66.
114. Chang BS, Lowenstein DH, Quality Standards Subcommittee of the American Academy of Neurology . Practice parameter: antiepileptic drug prophylaxis in severe traumatic brain injury. Neurology 2003; 60: 10–6.
115. Krumholz A, Wiebe S, Gronseth GS et al. Evidence‐based guideline: management of an unprovoked first seizure in adults. Neurology 2015; 84: 1705–13.
116. Ma CY, Xue YJ, Li M et al. Sodium valproate for prevention of early posttraumatic seizures. Chin J Traumatol 2010; 13: 293–6.
117. Glantz MJ, Cole BF et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 54: 1886–93.
118. Temkin NR. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilepsia 2001; 42: 515–24.
119. Badalian O.L., Burd S.G., Avakian G.N. et al. Sravnitel'naia otsenka effektivnosti i bezopasnosti proizvodnykh val'proevoi kisloty: opyt primeneniia. Epilepsiia i paroksizmal'nye sostoianiia. 2014; 6 (2): 39–44. (in Russian).
120.Badalyan O.L., Savenkov A.A. Modern conception of usage of injectable valproates  in status epilepticus. Consilium Medicum. 2019; 21 (2): 97–100. DOI: 10.26442/20751753.2019.2.190316 (in Russian).
121. Li XN, Shu Q, Su JM et al. Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol Cancer Ther 2005; 4: 1912–22.
122. Fu J, Shao CJ, Chen FR et al. Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines. Neuro-oncol 2010; 12: 328–40.
123. Weller M, Gorlia T, Cairncross JG et al. Prolonged survival with valproic acid use in the EORCT/NCIC temozolomide trial for glioblastoma. Neurology 2011; 77: 1156–64.
124. DeLorenzo RJ, Hauser WA, Towne AR et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology 1996; 46: 1029–35.
125. DeLorenzo RJ, Waterhouse EJ, Towne AR et al. Pepsistant nonconvulsive status epilepticus after the contrile of convulsive status epilepticus. Epilepsia 1998; 39: 833–40.
126. DeLorenzo RJ. Clinical syndromes and epidemiology of status epilepticus. In: H.Luders, S.Noachtar (eds.). Epileptic seizures pathophysiology and clinical semiology. Philadelphia: Churchill Livingstone, 2000; p. 697–710.
127. The drug treatement of status epilepticus in Europe: consensus document from a workshop at the first London Colloquium on Status Epilepticus. Epilepsia 2008; 49 (7): 1277–85.
128. Knake S, Hamer HM, Rosenow F. Status epiltpticus: a critical review. Epilepsy Behav 2009; 15: 10–4.
129. Larch J, Trinka E. Intravenous valproate in status epilepticus. A systematic review of the evidence. Epilepsia 2006; 47: 39–46.
130. Olsen KB, Taubоll E, Gjerstad L. Valproate is an effective, well-tolerated drug for treatment of status epilepticus/serial attacks in adults. Acta Neurol Scand Suppl 2007; 187: 51–4.
131. Yasiry Z, Shorvon SD. The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: a meta-analysis of published studies. Seizure 2014; 23: 167–74.
132. www.rlsnet.ru/tn_index_id_1803.htm
133. Karlov V.A., Andreeva O.V. Primenenie in"ektsionnogo depakina pri lechenii epilepticheskogo statusa. Russkii meditsinskii zhurnal. 2001; 20 (9): 889–93 (in Russian).

Н.В. Пизова

ФГБОУ ВО «Ярославский государственный медицинский университет» Минздрава России, Ярославль, Россия
pizova@yandex.ru